Company intelligence / Profile preview

Undisclosed U.S. entity

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Biotech Acquisition Company (BAC) was a Special Purpose Acquisition Company (SPAC) that completed a $230 million IPO in January 2021. It successfully entered a merger agreement with Blade Therapeutics, Inc. on November 8, 2021 (with closing expected in Q2 2022), to form Blade Biotherapeutics, Inc., thereby fulfilling its purpose as a blank check company. BAC is no longer active as a standalone entity.

Industry: Investors

Partnerships

Blade Therapeutics, Inc.Deerfield ManagementPfizer VenturesBristol Myers SquibbMPM CapitalOsage University Partners

Beyond the preview

Go deeper on Undisclosed U.S. entity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Undisclosed U.S. entity.

Explore the full profile